The paper discusses multiple steps the industry can take to ensure that patients have access to these treatments.
Neuropathy Action Foundation Releases White Paper On Adjusting Policies for Gene Therapies
You May Also Like
Global Launch Strategies in the Current Political Climate
February 19, 2025
FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk
February 19, 2025
Navigating Distrust: Pharma in the Age of Social Media
February 18, 2025
+ There are no comments
Add yours